Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Altos Labs is a privately held biotechnology company researching cellular rejuvenation programming. Its mission is to restore cell health and resilience through cellular reprogramming, with the goal of reversing disease, injury, and disability.
Primary product
Preclinical cellular rejuvenation and reprogramming technologies intended to become transformative medicines; no commercial product has been publicly disclosed.
Founded
2021
Headquarters
Redwood City, California, United States
Team size
Approximately 400–500 employees; public estimates vary
Work style
Onsite
Industry
Biotechnology
Sub-industry
Biotechnology research; cellular reprogramming; regenerative medicine; longevity therapeutics
18 jobs at Altos Labs
Offices
Business model
Stage
Private, heavily funded preclinical biotechnology company
Total raised
$3B
Latest round
Launch financing / reported Series A · Jan 2022
Latest amount
$3B
Launch financing / reported Series A
Jan 2022 · ARCH Venture Partners is frequently identified as a lead or principal institutional backer; the official announcement described the financing as committed by company builders and investors without providing a full allocation.
Leadership
CEO, Founder and Board Co-Chair
Hans Bishop
President, Founder and Board Co-Chair
Richard (Rick) Klausner
Chief Scientific Advisor, Founder and Board Co-Chair
Juan Carlos Izpisua Belmonte
Founding Scientist and Senior Vice President
Kevin Sin
Chief Financial and Business Officer
Joan Mannick
Senior Vice President, Chief Medical Officer and Head of Product Development
Dolo Diaz
Global Head and Senior Vice President of Drug Discovery and Development Sciences
Hana El-Samad
Senior Vice President and Director, Institute of Computation
Dan Elkes
Senior Vice President, Head of the Institute of Technology and Portfolio Management
Connie White
Chief People Officer
Laurie Hill
General Counsel and Chief Compliance Officer
Wolf Reik
Director, Cambridge Institute of Science
Jodi Nunnari
Director, Bay Area Institute of Science
Bikash Sabata
Vice President, Software and Platforms
Nimit Arora
Vice President, Finance and Accounting
Altos describes a collaborative, interdisciplinary and mission-driven workplace in which scientists, clinicians and computational researchers work across organizational boundaries. The company emphasizes intellectual freedom, diverse perspectives, openness, mentorship and translating breakthrough science into medicine.
Work style
Onsite
Compensation
Public reporting describes Altos as offering unusually competitive or lavish compensation to recruit prominent scientists, but current standardized salary bands and equity terms are not publicly available.
Benefits
Differentiators
Technology
Competitors
Estimated revenue
Not publicly verifiable. Altos is a private, precommercial biotechnology company with no disclosed commercial product or operating revenue; third-party estimates range from approximately $10 million to $50 million but should be treated as low-confidence.
Estimated monthly visits
54K
Traffic estimate as of Oct 2025
Altos Labs acquired Stanford-connected senotherapeutics startup Dorian Therapeutics. Financial terms were not disclosed. The transaction broadened Altos's publicly reported scope from cellular reprogramming toward senescence-targeting approaches.
SourceAltos appointed Joan Mannick as chief medical officer and head of product development, signaling an effort to advance its research toward clinical development. External reporting stated that Altos had not yet disclosed a clinical pipeline or initiated human trials.
SourceAltos Labs · Aug 2025
Altos appointed Joan Mannick to lead clinical programs and product development within its Institute of Medicine.
Endpoints News · May 2025
Altos acquired Dorian Therapeutics, a Stanford-connected startup developing senoblockers aimed at modulating cellular senescence. Deal terms were undisclosed.
Altos Labs / PR Newswire · Jun 2022
Altos committed to fund four Kyoto University CiRA research projects for five years to investigate cellular rejuvenation programming.
Altos Labs
Altos announced an Institute of Computation focused on AI, computational biology and models of cellular resilience.